Literature DB >> 31827910

Familial Exudative Vitreoretinopathy-Related Disease-Causing Genes and Norrin/β-Catenin Signal Pathway: Structure, Function, and Mutation Spectrums.

Hongtao Xiao1,2, Yuna Tong3, Yuxuan Zhu2,4, Min Peng5.   

Abstract

Familial exudative vitreoretinopathy (FEVR) is a hereditary ocular disorder characterized by incomplete vascularization/abnormality of peripheral retina. Four of the identified disease-causing genes of FEVR were NDP, FZD4, LRP5, and TSPAN12, the protein coded by which were the components of the Norrin/β-catenin signal pathway. In this review, we summarized and discussed the spectrum of mutations involving these four genes. By the end of 2017, the number of FEVR causing mutations reported for NDP, FZD4, LRP5, and TSPAN12 was, respectively, 26, 121, 58, and 40. Three most frequently reported mutations were c. 362G > A (p.R121Q) of NDP, c. 313A > G (p.M105V), and c.1282_1285delGACA (p.D428SfsX2) of FZD4. Mutations have a tendency to cluster in some "hotspots" domains which may be responsible for protein interactions.
Copyright © 2019 Hongtao Xiao et al.

Entities:  

Year:  2019        PMID: 31827910      PMCID: PMC6885210          DOI: 10.1155/2019/5782536

Source DB:  PubMed          Journal:  J Ophthalmol        ISSN: 2090-004X            Impact factor:   1.909


1. Introduction

Familial exudative vitreoretinopathy (FEVR), described first by Criswick and Schepens in 1969 [1], is a hereditary ocular disorder characterized by incomplete vascularization/abnormality of peripheral retina. Incomplete and aberrant vascularization leads to various complications, including retinal neovascularization and exudates, retinal fold and detachments, vitreous hemorrhage, and macular ectopia, ultimately leading to total blindness. FEVR is genetically heterogeneous and can be inherited as a dominant, recessive, or X-linked trait. The dominant form is the most common mode of inheritance. So far, mutations in at least 9 genes have been attributed to the development of FEVR including NDP, FZD4, LRP5, TSPAN12, ZNF408, KIF11, RCBTB1, CTNNB1, and JAG1 [2-10]. The proteins encoded by the first four genes are cooperative in the Norrin/β-catenin signaling pathway (also named as Norrin/Frizzled-4 pathway) and showed intense interaction with each other [11]. So, this review specially focused on the mutation spectrums of these genes. The mechanisms of NDP, FZD4, LRP5, and TSPAN12 in retinal vascular had been intensively investigated during the past years. The Ndp knockout mouse exhibited superficial retinal vasculature development delay and was unable to form deep retinal vasculature [12]. Similarly, FZD4 played a central role in vascular development in the eye and ear. Knockout of Fz4 has been shown to affect vascular development both in retinal and in inner ear and cause retinal stress [13, 14]. Compared with Fzd4 or Ndp knockout mice, Lrp5 knockout mice showed many milder vascular defects, in which attenuated retinal vessels and capillaries lacking lumen structure was observed [15, 16]. Afterwards, Tspan12 was verified to cause vascular defect and affect neural cells through association with Norrin/β-catenin but not Wnt/β-catenin signaling. Formation of microaneurisms, aberrant fenestration, and delayed hyaloid vessel regression was reported in Tspan12 knockout mice [11]. In the Norrin/β-catenin pathway, Norrin (coded by NDP) worked as a ligand, while Frizzled-4 (FZD4) acted as the receptor of Norrin, in concert with low-density lipoprotein receptor-related protein-5 (LRP5) as coreceptor. Norrin binds to FZD4 and its coreceptor LRP5, forming a ternary complex. Together with the auxiliary component tetraspanin-12 (TSPAN12), this complex initiates downstream β-catenin signaling. Specifically, FZD4-bound Dishevelled and phosphorylated LRP5 recruited Axin to the plasma membrane, resulting in the suppression of β-catenin phosphorylation/degradation. The cytoplasmic levels of β-catenin consequently increased. Subsequently, β-catenin was translocated to the nucleus where it interacts with the T-cell factor/lymphoid enhancing factor, family of transcription factors, to initiate RNA transcription and elongation, as shown in Figure 1 [17-19]. This signaling pathway shared many similarities with the canonical Wnt/β-catenin pathway except that Norrin substituted Wnt as the ligand and traspanin-12 had been linked to the Norrin/β-catenin signaling pathway. Norrin/Frizzled-4 signaling plays an important role in retinal vascular growth, remodeling, and maintenance [20].
Figure 1

A schematic of the Norrin/β-catenin signal pathway. When Norrin was bond to the receptor complex FZD4/LRP5/TSPAN12, Dishevelled and Axin would be recruited to FZD5 and LRP5. Consequently, β-catenin escaped from the degradation complex and entered nucleus to initiate gene transcription collaborated with T-cell factor/lymphoid-enhancing factor.

Prior to this review, a great many mutations in NDP, FZD4, LRP5, and TSPAN12 had been reported by different study groups from different countries as disease-causing mutation of FEVR. Although most of the mutations were documented for once by one study group, some mutations seemed to be more common than others. Here, we presented the comprehensive list of currently known mutations in NDP, FZD4, LRP5, and TSPAN12 associated with FEVR and discussed their coding consequences. This aims in facilitating the construction of a complete spectrum of mutations that occur in the above four genes. We discuss about each gene mutation individually and then highlight how they disturb the protein interactions.

2. Materials and Methods

The current review article aimed to analyze the studies on FEVR caused by NDP, FZD4, LRP5, and TSPAN12 gene mutations to find the spectrum of these four genes. For this review study, an extensive search in PubMed and Web of Science up to December 30, 2017, was conducted independently by two individuals (Tong and Zhu) using the following search terms: “Familial exudative vitreoretinopathy” and “mutation”. To avoid losing relevant information, no limitations were set in the search. Furthermore, the related studies and the references of literatures were manually screened for additional potential eligible studies. Mutations in NDP can result in Norrie disease and X-linked exudative vitreoretinopathy. Some earlier reports investigated Norrie disease (ND) and FEVR together. In addition, loss-of-function mutations in the LRP5 gene either cause osteoporosis pseudoglioma syndrome (OPPG) or FEVR depending on the functional severity of mutation. These distinct clinical entities share some common pathological features such as abnormal retinal blood vessel growth that may result in retinal detachment. So, we read the relevant articles of the candidates carefully to make sure the probands on whom the mutations were found were definitely diagnosed as FEVR. Then, we recorded the mutations related to FEVR and excluded those caused ND and OPPG. A total of 433 potentially relevant articles were identified, but only 41 studies involving FEVR patients caused by NDP, FZD4, LRP5, and TSPAN12 gene mutations were included in this review.

3. Results

3.1. NDP Mutations and Norrin Structure

The NDP gene locus mapped to chromosome Xp11.4 and comprised three exons. However, the first exon corresponds to the untranslated region of the gene that has regulatory functions, and only exons 2 and 3 of encode a secreted protein of 133 amino acids called Norrin or Norrie disease protein. Norrin consists of two major parts: a signal peptide at the amino-terminus of the protein that directs its localization and a region containing a typical motif of six cystines forming a cystine-knot. The cystine-knot motif is highly conserved in many growth factors as transforming growth factor-β, human chorionic gonadotropin, nerve growth factor, and platelet derived growth factor [21]. Cystine residues and their disulfide bonds in the cystine-knot play important structural and functional roles. Among 10 Frizzled family members, Norrin specifically binds to the transmembrane FZD4 with high affinity, forming a Norrin/FZD4 complex with LRP5 and TSPAN12 coreceptors to activate the Norrin/β-catenin signaling pathway [22]. Norrin was also reported to play a major role in controlling retinal vascular growth and architecture both in the developing eye and in adult vasculature. Twenty-six nucleotide variants have been identified for NDP in patients with FEVR. These include 21 missense changes, 4 deletions, and 1 insertion resulting frame shift [2, 23–31] (Table 1 and Figure 2). Most of the mutations were found in single or only a few patients, while several mutations are generally more common. By far, the most prevalent mutation was c.362G > A (p.R121Q), distributed in Spanish, Mexican, Indian, Chinese, and Italian. It is noteworthy that although probands containing c.11_12delAT (p.H4RfsX21), c.170C > G (p.S57X), and c.310A > C (p.K104Q) were definitely diagnosed as FEVR following explicit criteria, these three mutations were also reported to cause Norrie disease by other researches [28, 32, 33]. The ocular features and retinal changes observed in Norrie disease are similar to those observed in cases of FEVR. Not all the Norrie disease patients have mental retardation and develop a progressive sensorineural hearing loss; it is really difficult to distinguish Norrie disease from FEVR.
Table 1

Spectrum of NDP gene mutations among patients with familial exudative vitreoretinopathy.

StudiesNo. of patientsNo. of mutationsDNA variantCoding effectLocation of the amino residueMutant phenotypesCountry of origin
Chen et al. [2]301c.370C>Tp.L124FNorrin dimer interfaceRetina detachedUK
Riveiro-Alvarez et al. [30]451c.362G>Ap.R121QNorrin dimer interfaceCongenital blindness, phthisis bulbiSpain
Dickinson et al. [23]131c.307C>Gp.L103VNorrin-FZD4 interfaceNot mentionedAustralia
Hiroyuki et al. [34]623c.53T>Ap.I18KSignal domainPeripheral avascularization, neovascularizationJapan
c.162G>Cp.K54NDeductive Norrin-LRP5 interfaceRetinal detachment and macular traction with temporal avascularization
c.344G>Tp.R115LDeductive Norrin-LRP5 interfaceRetinal detachment
Pelcastre et al. [35]1273c.361C>Tp.R121WNorrin dimer interfaceOn-perfusion in peripheral retinaMexico
c.362G>Ap.R121QNorrin dimer interfaceRetinal detachment
Musada et al. [36]1108c.11_12delATp.H4RfsX21Signal domainBilateral total retinal detachmentIndia
c.69delCp.D23EfsX9Signal domainPigmentation and vitreoretinal traction
c.142_145delATCAp.I48VfsX55Premature terminationBilateral leukocoria and total retinal detachment
c.148C>Gp.H50DDeductive Norrin-LRP5 interfaceStraightening of the blood vessel, macular dragging
c.170C>Gp.S57XNorrin-FZD4 interfaceRetinal detachments and retrolental membranes
c.338G>Ap.G113DNear deductive Norrin-LRP5 interfaceAvascular peripheral retina, straightening of the blood vessels, and dye leakage
c.362G>Ap.R121QNorrin dimer interfaceRetinal detachments with retrolental membranes
c.376T>Cp.C126RNorrin dimer interfaceBilateral total retinal detachment
Liu Y. L. et al. [37]401c.310A>Cp.K104QNorrin-FZD4 interfaceWeak eyesight, retinal vascular abnormalitiesChina
Tang et al. [31]1005c.196G>Ap.E66KCystine-knot motifMacular draggingChina
c.203A>Cp.H68PCystine-knot motifEctopic macular
c.281A>Tp.H94LNorrin dimer interfacePeripheral avascular zone and retinal exudates
c.362G>Ap.R121QNorrin dimer interfaceRetinal fold, retinal detachment
c.334delGp.G113AfsX149Premature terminationBilateral tractional retinal detachment
Iarossi et al. [24]82c.362G>Ap.R121QNorrin dimer interfaceFalciform fold, partial tractionItalian
c.313G>Cp.A105FNorrin-FZD4 interfaceMacula-involving retinal detachment
Rao et al. [29]313c.127C>Ap.H43NNorrin-FZD4 interfaceComplete retinal detachmentChina
c.52_53ins32bpp.S29fsPremature terminationComplete retinal detachment
c.195C>Gp.C65WCystine-knot motif, form disulfide bond with C126Complete retinal detachment
Figure 2

Schematic diagram of the Norrin protein shows the location of the mutations within the protein domains. Superscript number means the reported times of the same or different mutations at a certain site. The color of the mutations which were reported more than one time was recolored as orange. The opacity varied with the reported frequency of the mutations.

It was demonstrated from the three-dimensional structure of Norrin that two-monomer Norrins formed a homodimer in the crystal. The Norrin monomer contained exclusive β strands with two β-hairpins on one side and one β-hairpin on the other side. Crystal structures of Norrin in complex with the extracellular domain of FZD4 showed that two β-hairpins in Norrin (β1-β2 and β5-β6) interacted with three loops in FZD4 cystine-rich domain (FZD4-CRD) [38, 39]. There were 19 mutations located in domains from C39 to C65 and C96 to C126, which covered two β-hairpins (β1-β2 and β5-β6) and loops between them, namely, 73% of the mutations (19/26) concentrated in the interacting domains with FZD4-CRD. Specifically, 9 mutations were located in the Norrin dimer interface which was formed from β2 and β4 sheets of one monomer and β2′ of another monomer (Table 1). Three mutations were reported from the cystine-knot motif, one of which (C65W) obviously impaired intermolecular disulfide bond-forming. Five mutations disturbed the hydrogen bonds or hydrophobic contacts between Norrin and FZD4 CRD in the Norrin-FZD4 CRD interface [38, 40]. Four mutations clustered on the edge of the Norrin molecule in the β1-β2 and β3-β4 loop regions were inferred as LRP5 binding sites because they did not affect Fz4 binding yet reduced the ability of Norrin to activate the TCF reporter [39]. The residues in the interaction interface are well defined and overlap with disease-associated mutations in NDP. The level of signaling activity of K104Q, R121Q, and L124F was between 20% and 80% of the wide-type Norrin, suggesting that even a modest decrement in Norrin/Fz4 signaling may have a significant phenotypic effect in humans [14, 41]. It is of no surprise that the mutations located in β1-β2 and β5-β6 obstructed the formation of two β-hairpins and the interactions between Norrin and FZD4.

3.2. FZD4 Mutations and FZD4-CRD Structure

The FZD4 gene is located on chromosome 11q14.2, and its mRNA consists of two exons coding for 537 amino acid protein called FZD4 or Frizzled-4 protein. FZD4 acted as the receptor for Wnt and Norrin along with LRP5, which has a pivotal role in various cellular processes including cell fate determination, control of cell polarity, and malignant transformation. The FZD4 contains a ∼120-residue N-terminal extracellular cystine-rich domain(CRD), seven helix transmembrane domains, three extracellular and three intracellular loops, and a C terminal cytoplasmic domain [42, 43]. The cystine-rich domain is indispensable to Wnts or Norrin and is conserved among Frizzled family members [22, 39]. The FZD4 carboxyl cytoplasmic region contains juxtamembrane KTXXXW motif which is responsible for association with Dishevelled to activate downstream signaling [44, 45]. In this update, we summarized a total of 121 mutations already reported in patients with FEVR in the literatures consisting of 70 missense mutations, 19 nonsense mutations, and 30 insertions or deletions that lead to either frame shifts or in-frame deletions; a single base change resulted in 2 amino acids extension and a whole-gene deletion [7, 24, 28, 29, 46–71] (Table 2 and Figure 3). No splice mutations have been reported for FZD4, and the mutations seem to cluster in two specific “hotspots”. Although the mutations span in whole FZD4 gene, 49% (59 of 121 mutations) and 13% (16 of 121 mutations) of them have a tendency to bunch in the N terminal extracellular domain and C terminal intracellular domain, respectively.
Table 2

Spectrum of FZD4 gene mutations among patients with familial exudative vitreoretinopathy.

StudiesNo. of patientsNo. of mutationsDNA variantCoding effectLocation of the amino residueMutant phenotypeCountry of origin
Zhang et al. [65]495c.134G>Ap.C45YCRD domain, no plasma membrane localization, failed to mediate Norrin induction of these β-catenin target genesNot mentionedChina and USA
c.173A>Gp.Y58CCRD domain, failed to bind Norrin, failed to mediate Norrin induction of these β-catenin target genesNot mentioned
c.610T>Cp.C204RCRD domain, failed to bind Norrin, failed to mediate Norrin induction of these β-catenin target genesNot mentioned
c.678G>Ap.W226XTransmembrane 1, failed to mediate Norrin induction of these β-catenin target genesNot mentioned
c.1488G>Ap.W496XC-terminal intracellular domain, failed to mediate Norrin induction of these β-catenin target genesNot mentioned

Drenser et al. [48]1235c.97C>Tp.P33SSignal sequence2-stage FEVR, rhegmatogenous retinal detachmentUSA
c.349T>Cp.C117RCRD domain, conserved cystine residue4B stage FEVR
c.502C>Tp.P168SCRD domain2-stage FEVR, rhegmatogenous retinal detachment
c.542G>Ap.C181YCRD domain, conserved cystine residue4B stage FEVR
c.1513C>Tp.Q505XImmediately downstream from KTxxxW motif4B stage FEVR

Qin et al. [56]562c.1005G>Cp.W335CHighly conserved across all members of the FZD familyBilateral retinal foldsJapan
c.1024A>Gp.M342VIntracellular loop 2, function not shownBilateral dragged disc

Robitaille et al. [7]272c.1479_1484delp.M493_W494delFailed to activate calcium/calmodulin-dependent protein kinase II and protein kinase CBilateral retinal detachmentCanada
c.1501_1502delCTp.L501fsX533No membrane accumulation, failed to activate calcium/calmodulin-dependent protein kinase II and protein kinase CNot mentioned

Kondo et al. [51]244c.313A>Gp.M105VCRD domainBilateral vitreous opacity, retinal exudates, macular ectopia, falciform retinal foldJapan
c.957G>Ap.W319XTransmembrane domainFalciform retinal fold, chronic retinal detachment
c.1250G>Ap.R417QIntracellular loop 3Falciform retinal fold, posterior synechiae, chronic retinal detachment
c.1463G>Ap.G488DTransmembrane domainFalciform retinal folds
Dailey et al. [47]42111c.40 Del/inserUnknownNot mentionedNot mentionedUSA
c.97C>Tp.P33SSignal sequence, reduced Wnt reporter activityNot mentioned
c.151T>Ap.S51TCRD domainNot mentioned
c.169G>Tp.G57CCRD domainNot mentioned
c.349T>Cp.C117RCRD domainNot mentioned
c.502C>Tp.P168SCRD domain, reduced Wnt reporter activityNot mentioned
c.542G>Ap.C181YCRD domainNot mentioned
c.758G>Ap.R253HTransmembrane domainNot mentioned
c.1074A>Cp.K358NTransmembrane domainNot mentioned
c.1513C>Tp.Q505XImmediately downstream from KTxxxW motifNot mentioned
c.1589G>Ap.G530EC-terminalNot mentioned

Fei et al. [49]613c.C205Tp.H69YCRD domainNot mentionedChina
c.G400Tp.E134XCRD domain, failed to activate β-catenin reporterPeripheral avascular zone, dragged disc
c.1506delACp.T503fsFailed to activate β-catenin reporterTotal retinal detachment

Yang et al. [69]565c.313A>Gp.M105VCRD domainIncreased branching of peripheral vessels, retinal detachment, Avascular zone, Retrolenticular fibrotic mass, neovascularizationChina
c.631T>Cp.Y211HLinker upstream of transmembrane 1Temporal dragging of optic disc, peripheral fibrous proliferation
c.1282-1285delGACAp.D428SfsX2Intracellular loop 3Straightening of temporal arcades, temporal dragging of optic disc, peripheral fibrous proliferation
c.1482G>Ap.W494XTransmembrane domainRetrolenticular fibrotic mass, lens dislocation, brushlike peripheral, avascular zone, neovascularization, peripheral fibrous proliferation
c.1513C>Tp.Q505XImmediately downstream from KTxxxW motifTemporal dragging of optic disc, f alciform retinal fold, branching of peripheral vessels, avascular zone, peripheral exudates

Nallathambi et al. [55]753c.97C>Tp.P33SSignal sequence, reduced Wnt reporter activityPeripheral lattice degeneration, atrophic holes, macular ectopia, bilateral peripheral avascular zoneIndia
c.244_251del8ins27p.F82fsX135CRD domainMacular ectopia, terminal branching, peripheral avascular zone
c.610T>Cp.C204RCRD domainTemporal peripheral avascular zone, terminal branching, tractional retinal detachment
Seo et al. [59]519c.160C>Tp.Q54XCRD domain1B stage FEVRKorea
c.313A>Gp.M105VCRD domain1B,1A, 2B stage FEVR
c.456C>Gp.N152KCRD domain1B, 2B stage FEVR
c.470T>Cp.M157TCRD domain1B stage FEVR
c.539_540delAGp.E180VfsX9CRD domain1B, 3A stage FEVR
c.676T>Ap.W226RLinker upstream of transmembrane 11B, 3A stage FEVR
c.1210_1211delTTp.L404VfsX54Transmembrane domain1A stage FEVR
c.1282_1285delGACAp.D428SfsX2Intracellular loop 31A stage FEVR
Whole gene deletionNo proteinNo protein2B stage FEVR

Musada et al. [66]1107c.313A>Gp.M105VCRD domainDiagnosed with FEVR, symptoms not mentionedIndian
c.341T>Gp.I114SCRD domainDiagnosed with FEVR, symptoms not mentioned
c.470T>Cp.M157TCRD domainDiagnosed with FEVR, symptoms not mentioned
c.1282_1285delGACAp.D428SfsX2Intracellular loop 3Diagnosed with FEVR, symptoms not mentioned
c.1286_1290delAGTTAp.K429RfsX28Intracellular loop 3Diagnosed with FEVR, symptoms not mentioned
c.1395_1396insTp.R466SfsX6Extracellular loopDiagnosed with FEVR, symptoms not mentioned
c.1613A>Cp.X538SextX2C-terminusDiagnosed with FEVR, symptoms not mentioned

Jia et al. [50]4812c.39-49delCCCGGGGGCGp.P14fsX57Signal sequence, Truncated proteinAvascular retina, dragged maculaChina
c.65G>Ap.G22ESignal sequence, loss of activityNystagmus, retrolental fibroplasia, retinal detachment
c.205C>Tp.H69YCRD domain, loss of activityAvascular retina, fibrous proliferation, and dragged macula
c.313A>Gp.M105VCRD domain, loss of activityRetinal vascular tortuosity, exudates, and avascularization
c.538G>Ap.E180KCRD domain, loss of activityNot mentioned
c.710C>Gp.T237RLinker upstream of transmembrane 1, loss of activityPreretinal fibrosis, peripheral nonperfusion
c.757C>Tp.R253CTransmembrane domain, loss of activityPeripheral avascularization and typical scalloped border
c.983T>Cp.F328STransmembrane domain, loss of activityRetinal folds and persistent hyperplastic primary vitreous
c.1015G>Ap.A339TIntracellular loop 2, loss of activityDragged discs, retinal elevation with hemorrhage
c.1408G>Ap.D470NTransmembrane domain, loss of activityDragged discs, retinal folds, and macular ectopia
c.1472C>Ap.S491XTransmembrane domain, truncated proteinDragged discs, macular ectopia, and pigment changes
c.1488G>Ap.W496XC-terminus, truncated proteinNot mentioned

Peachey et al. [70]11c.1026A>Gp.M342VIntracellular loop 2Straightening of the retinal vessels, peripheral avascular areasJapanese
Tang et al. [60]10014c.107G>Ap.G36DSignal sequenceNot mentionedChina
c.133T>Cp.C45RCRD domainAvascular zone, increasing of peripheral vessels, straightening of vessels
c.133T>Ap.C45SCRD domainNot mentioned
c.134G>Ap.C45YCRD domainNot mentioned
c.158G>Cp.C53SCRD domainMacular dragging, Avascular zone, increasing of peripheral vessels, straightening of vessels
c.223G>Ap.A75TCRD domainNot mentioned
c.268T>Cp.C90RCRD domainNot mentioned
c.313A>Gp.M105VCRD domainNot mentioned
c.957G>Ap.W319XTransmembrane domainAvascular zone, increasing of peripheral vessels
c.975_978delCACTp.T326fsX356Transmembrane domainAvascular zone, neovascularization, increasing of peripheral vessels, SV
c.1034_1054delCTTATTTCCACATTGCAGCCTp.S345_A351delIntracellular loop 2Avascular zone, increasing of peripheral vessels, straightening of vessels
c.1282_1285delGACAp.D428SfsX2Intracellular loop 3Not mentioned
c.1475delGp.G492fsX512Intracellular loop 3Avascular zone, neovascularization, increasing of peripheral vessels, straightening of vessels,vessels exudates
c.1498delAp.T500fsX512Truncated proteinNot mentioned

Nikopoulos et al. [68]165c.118G>Cp.E40QSignal sequenceNot mentionedNetherlands
c.611G>Ap.C204YCRD domainDeformation of posterior retina, ectopia of the macula, stretched retinal vessels, retinal detachment
c.856G>Tp.E286XExtracellular loopFew abnormal temporal retinal branches, avascular peripheral fundus
c.1282_1285delp.D428SfsX2Intracellular loop 3Macular ectopia. Haemorrhagic and exudative areas present in the retina
c.1573G>Cp.G525RC-terminusMacular ectopia and peripheral, retinal detachment

Kondo et al. [25]11c.1250G>Ap.R417QIntracellular loop 3retrolental fibroplasia, falciform retinal foldJapanese
Toomes et al. [69]408c.107G>Ap.G36DSignal sequenceUnable to obtain detailed clinical notesUK
c.314T>Cp.M105TCRD domainMacula-off rhegmatogenous retinal detachment, inadequate vascularization
c.469A>Gp.M157VCRD domainMacular folds and retinal detachments
c.957delGp.W319fsX323Transmembrane domainPeripheral retinal fold
c.1490C>Tp.S497FC-terminusDisc-dragging
c.1498delAp.T500fsX512KTxxxW domainSmall myopic optic disc, diffuse nonspecific pigmentary changes
c.1501_1502delCTp.L501fsX533KTxxxW domainBilateral cicatrized tractional retinal detachments
c.1513C>Tp.Q505XImmediately downstream from KTxxxW motifTemporal sector of retina with deficient vascularization

Robitaille et al. [57]6811c.316 T>Cp.C106GCRD domainDragging of the retina, macular foldCanadian
c.470T>Ap.M157KCRD domainPeripheral pigmentary, total retinal detachment, nonperfusion with leucocoria
c.633delCp.Y211fsXLinker upstream of transmembrane 1Haemangiomatous lesion with exudation and peripheral avascular retina
c.1282_1285delp.D428SfsX2Intracellular loop 3Left macula dragged
c.1463G>Tp.G488VTransmembrane domain
c.1508insCp.T503fsX31KTxxxW motifBilateral dragging of the macula with peripherally straightened, avascular retina
c.313A>Gp.M105VCRD domainBilateral dragging of the macula, retina detachment
c.678G>Ap.W226XLinker upstream of transmembrane 1Large elevated tight fold, large falciform fold
c.1448G>Ap.W496XC-terminal intracellular domainTractional retinal detachment
c.1479_1484delp.M493_W494delTransmembrane domainNot mentioned
c.341T>Cp.I114TCRD domainNot mentioned
Robitaille et al. [67]52c.1479_1484delp.M493_W494delTransmembrane domainAbsence of retinal vasculature, hypoplastic iris with posterior synechiaeCanadian
c.341T>Cp.I114TCRD domainFalciform retinal folds, small atrophic retinal hole

Boonstra et al. [46]834c.668T>Ap.M223KLinker upstream of transmembrane 1Diagnosed with FEVR, symptoms not mentionedNetherlands
c.957G>Ap.W319XTransmembrane domainDiagnosed with FEVR, symptoms not mentioned
c.1333A>Cp.T445PTransmembrane domainDiagnosed with FEVR, symptoms not mentioned
c.1448G>Ap.W496XC-terminus, truncated proteinDiagnosed with FEVR, symptoms not mentioned

Iarossi et al. [24]83c.277C>Tp.Q93XCRD domainLarge avascular area, falciform retinal foldItalian
c.542G>Ap.C181YCRD domainStage 3 and stage 2 FEVR
c.611G>Tp.C204FCRD domainStage 4A FEVR

Rao et al. [29]312c.1282_1285delGACAp.D428SfsX2Intracellular loop 3Complete retinal detachmentChina
c.227delAp.E76fsCRD domainFalciform retinal detachment.

Murken et al. [53]11c.1474delGp.G492fsXIntracellular loop 3Peripheral avascular zone and macular draggingMexico

Schatz and Khan [58]31c.349T>Cp.C117RCRD domain, forms a disulfide bond with Cys158Mild temporal avascularity, mild peripheral temporal avascularitySweden
Figure 3

Schematic diagram of the Frizzled-4 protein shows the locations of the mutations. A whole gene deletion and a deletion/insertion (c.40 del/inser) with unknown protein change are not shown. Superscript number means the reported times of the same or different mutations at a certain site. The color of the mutations which were reported more than one time was recolored as orange. The opacity varied with the reported frequency of the mutations.

The 120-residue N-terminal extracellular cystine-rich domain (CRD) domain, connected to the first transmembrane helix by a 50-amino-acid linker, was crucial to ligand recognition. In the CRD domain, mutations at C45, M105, and M157 were three most frequently reported mutations, for 4, 9, and 4 times by different studies, respectively. One of these mutations, C45Y, was found to disrupt protein folding, resulting FZD4 being stuck in the cytoplasm with no membrane location [71]. It was supposed that the disulfide bond between Cys45 and Cys106 was imperative to protein transportation and functional activity. It was also visible from the crystal structure of FZD4-CRD that five disulfide bridges (Cys45Cys106, Cys53Cys99, Cys90Cys128, Cys117Cys158, and Cys121Cys145) stabilized the α helices [38]. Two crystal structures of Norrin/FZD4-CRD complex and a FZD4 transmembrane domain had been registered in the Protein Data Bank [38, 40, 70]. The structures showed that one FZD4-CRD coupled a Norrin monomer with no interactions between the two FZD4-CRDs. Three loops between α helices were responsible for binding to the β-hairpins in Norrin [38]. The C-terminal tail of FZD4-CRD also made contribution to Norrin recognition. Residues V45, M59, L61, and L124 of Norrin and F96, M105, I110, M157, and M159 FZD4-CRD constituted a hydrophobic core at the binding interface [40]. Based on this, it is speculated that FEVR-related mutations at M105 and M157 may interrupt the binding of Norrin to FZD4. Biophysical analysis of Norrin and FZD4 demonstrated that the linker region of FZD4 contributes to a high-affinity interaction with Norrin and signaling [71]. Mutation C181Y in this domain not only destroyed the disulfide bond but also interrupted the binding of Norrin. The FZD4 transmembrane domain structure showed mutations in key positions (M309L, C450I, C507F, and S508Y) of the ΔCRD-FZD4 structure which led to aberrant downstream signaling. However, no disease-causing mutation had been reported in abovementioned four amino residuals. The FZD4-mediated membrane recruitment of the cytoplasmic effector Dishevelled is a critical step in Wnt/β-catenin signaling. Considerable domains on FZD4 were identified as critical sites for recruitment of Dishevelled. A conserved motif (KTxxxW) located two amino acids after the seventh transmembrane domain was firstly verified to be crucial for membrane relocalization and phosphorylation of Dishevelled [44, 45]. The interaction between FZD4 and Dishevelled was further found to be pH- and charge-dependent [72]. Several amino residuals in intracellular loops 1, 2, and 3 and the flanking region near to intracellular loop 3 were also important for the intracellular location of Dishevelled while the mutant impaired the binding of Dishevelled [73-77]. Research based on FZD6 also showed that the linker domain, especially some conserved cystines, between the CRD domain and seven transmembrane core was imperative for Dishevelled recruitment [78]. One potential mechanism for FZD4 activation would be a Wnt/Norrin-induced movement of the seventh transmembrane domain to expose the key FZD4-Dishevelled interaction site [79]. Although 21% (26 of 121 mutations) of the mutations aggregated in the third intracellular loop and C terminal intracellular domain, it was not clear how the mutations affect the interaction between FZD4 and Dishevelled.

3.3. LRP5 Mutations and LRP5/LRP6 Structure

LRP5 gene, localized on human chromosome 11q13.2, consists of 23 exons and encodes 1615 amino acid single-pass transmembrane protein. LRP5 is a member of the low-density lipoprotein receptor family and belongs to a subfamily consisting of its mammalian homolog LRP6 and the Drosophila protein arrow. LRP5 and LRP6 share 73% identity in their extracellular domains. The LRP5/6 protein contains three domains including an extracellular domain, one transmembrane domain, and a cytoplasmic domain. The LRP5/6 ectodomain contains four β-propeller motifs (composed of six YWTD repeats) at the amino terminal end that alternate with four epidermal growth factor- (EGF-) like repeats (YWTD-EGF domain). These are followed by three low-density-lipoprotein receptor-like ligand-binding domains. LRP5 can act synergistically with FZD4 or other members of the Frizzled family to bind Wnts or Norrin, forming a functional ligand-receptor complex that triggers canonical Wnt/β-catenin or the Norrin/β-catenin signaling pathway and induce the transcription of target genes subsequently [80, 81]. Thus far, 58 causative mutations identified in patients with FEVR have been reported for LRP5, of which 46 mutations are missense changes, 6 frame shift mutations resulted by deletions, insertion, and duplication, 2 introduce premature stop codons, and 4 changes affect splicing [28, 29, 31, 46, 56, 59, 69, 69, 82–85] (Table 3 and Figure 4). Mutations located in first, second, and third YWTD-EGF domain accounted for 12% (7 of 58 mutations), 38% (22 of 58 mutations), and 17% (10 of 58 mutations) of all the mutations, respectively. Thus, it can be seen causative mutations have a trend of clustering in the second YWTD-EGF domain since this segment is composed of only about 300 amino acids, accounting for less than 20% of whole LRP5 protein. Five of the included mutations (c.1828G>A, c.731C>G, c.1042C>T, c.1058G>A, and c.1481G>A) were also reported as causative mutation for OPPG [86], which was characterized as blindness and decreased bone density. But FEVR and OPPG were two different diseases because of the distinct pathogenesis of visual loss. OPPG patients often presented with blindness in the neonatal period and the symptoms initiated during early childhood. Inconformity of these results may was due to omission of bone density and definite pathogenesis of visual loss.
Table 3

Spectrum of LRP5 gene mutations among patients with familial exudative vitreoretinopathy.

StudiesNo. of patientsNo. of mutationsDNA variantCoding effectLocation of the amino residueMutant phenotypeCountry of origin
Toomes et al. [68]326c.518C>Tp.T173MFirst β-propeller motifAbnormal retinal vasculature and retinal foldUSA
c.3502T>Cp.Y1168HLow-density-lipoprotein receptor-like ligand binding domainsTotal retinal detachment and retinoschisis
c.3840delAp.R1270fsX1438Premature terminationNot mentioned
c.4081T>Gp.C1361GLow-density-lipoprotein receptor-like ligand binding domainsClassic features of FEVR
c.4119_4120insCp.K1374fsX1549Premature terminationNot mentioned
c.4488 + 2T>GSplice-donor mutationPremature terminationUndetermined

Qin et al. [56]569c.433C>Tp.L145FFirst β-propeller motifBilateral retrolental fibroplasias and total retinal detachmentJapan
c.803_812delp.G268fsX272Premature terminationBilateral dragged macula
c.1330C>Tp.R444CSecond β-propeller motifSevere falciform retinal fold
c.1564G>Ap.A522TSecond β-propeller motifTractional retinal detachment, severe macular ectopia along with peripheral fibrovascular mass
c.1604C>Tp.T535MSecond β-propeller motifBilateral retinal folds followed by total retinal detachment
c.1828G>Ap.G610RSecond epidermal growth-like factorBilateral dragged macula
c.1850T>Gp.F617CSecond epidermal growth-like factorBilateral retinal folds followed by total retinal detachment
c.2392A>Gp.T798AThird β-propeller motifBilateral peripheral avascular retinas
c.3361A>Gp.N1121DFourth β-propeller motifUnilateral falciform retinal fold with bilateral retinal avascularization

Boonstra et al. [46]832c.1532A>Cp.D511ASecond β-propeller motifDiagnosed with FEVR, symptoms not mentionedNetherlands
c.2413C>Tp.R805WThird β-propeller motifDiagnosed with FEVR, symptoms not mentioned

Nikopoulos et al. [28]164c.1321G>Ap.E441KSecond β-propeller motifNot mentionedNetherlands
c.2978G>Ap.W993XEGF-like domain following the third “β-propeller” moduleNot mentioned
c.3758G>Tp.C1253FEGF-like domain following the third “β-propeller” moduleNot mentioned
c.4489-1G>ASplice defectNot applicatedNot mentioned

Yang et al. [69]496c.891-892delTCp.R298LfxX2Premature terminationRetrolenticular fibrotic mass, retinal detachment, microcornea, flat anterior chamberChina
c.2484C>Gp.I828MThird β-propeller motifRetrolenticular fibrotic mass, stretched ciliary process
c.2626G>Ap.G876SThird epidermal growth like factorRetrolenticular fibrotic mass, stretched ciliary process
c.3361A>Gp.N1121DFourth β-propeller motifTemporal dragging of optic disc, retrolenticular fibrotic mass
c.4025G>Ap.R1342QLow-density-lipoprotein receptor-like ligand binding domainsMicrocornea, retrolenticular fibrotic mass, avascular zone
c.4087G>Ap.D1363NLow-density-lipoprotein receptor-like ligand binding domainsIncreased branching of peripheral vessels, retrolenticular fibrotic mass

Fei et al. [82]22c.1264G>Ap.A422TSecond β-propeller motifNot mentionedChina
c.1619T>Cp.L540PSecond epidermal growth like factorNot mentioned

Seo et al. [59]514c.731C>Gp.T244RFirst β-propeller motif3A/2B stage FEVRKorea
c.1330C>Tp.R444CSecond β-propeller motif2A stage FEVR
c.1833dupGp.C612VfsX25Premature termination1B/4A stage FEVR
c.4098C>Gp.D1366ELow-density-lipoprotein receptor-like ligand binding domains3B stage FEVR

Zhang et al. [85]44c.C1042Tp.R348WFirst epidermal growth-like factorNot mentionedChina
c.G1141Ap.D381NSecond β-propeller motifNot mentioned
c.C1870Tp.R624WSecond epidermal growth-like factorNot mentioned
c.A4550Gp.Y1517CCytoplasmic tailNot mentioned

Tang et al. [31]10010c.1058G>Ap.R353QFirst epidermal growth-like factorIlateral retrolenticular fibrotic mass and total retinal detachmentChina
c.1183C>Tp.R395WSecond β-propeller motifFalciform retinal fold
c.1318A>Tp.I440FSecond β-propeller motifRetinal fold
c.1582G>Ap.E528KSecond β-propeller motifPeripheral vascular deficiencies
c.1942G>Ap.V648ISecond epidermal growth-like factorRhegmatogenous retinal detachment
c.2738G>Tp.C913FThird epidermal growth-like factorRetinal fold and macular dragging
c.4087G>Cp.D1363HLow-density-lipoprotein receptor-like ligand binding domainsFalciform retinal fold
c.4733C>Tp.T1578MCytoplasmic tailRetinal fold
c.92-2A>CSplice site mutationPremature terminationIlateral retrolenticular fibrotic mass and total retinal detachment
c.4488 + 2T>GSplice site mutationPremature terminationRetinal folds

Rao et al. [29]315c.4205G>Ap.G1402DTransmembrane domainFalciform foldChina
c.2237G>Cp.R746PThird β-propeller motifPeripheral avascular zone
c.2618A>Tp.K873MThird β-propeller motifPeripheral avascular zone
c.1384C>Tp.R462XSecond β-propeller motifComplete retinal detachment
c.2817_2827+1del12bpp.N940fsPremature terminationComplete retinal detachment

Liu et al. [83]105c.542T>Gp.M181RFirst β-propeller motifDiagnosed with FEVR, symptoms not mentionedChina
c.1197G>Tp.R399SSecond β-propeller motifDiagnosed with FEVR, symptoms not mentioned
c.1481G>Ap.R494QSecond β-propeller motifDiagnosed with FEVR, symptoms not mentioned
c.1507G>Ap.G503RSecond β-propeller motifDiagnosed with FEVR, symptoms not mentioned
c.2626G>Ap.G876SThird epidermal growth-like factorDiagnosed with FEVR, symptoms not mentioned

Pefkianaki et al. [84]11c.2234C>Tp.A745VThird β-propeller motifExtensive exudative retinopathy and shallow retinal detachmentUSA
Figure 4

Schematic representation of LRP5 protein shows the location of the mutations within the protein domains. Four splice site mutations are not shown. Superscript number means the reported times of the same or different mutations at a certain site. The color of the mutations which were reported more than one time was recolored as orange. The opacity varied with the reported frequency of the mutations.

In the crystal of the first two YWTD-EGF structure of LRP6, each of the two EGF domains packs tightly against the bottom surface of the preceding YWTD β-propellers [87]. Extensive interface interactions was observed between the first β-propellers and second β-propellers, and the first EGF domain also interacts with the second β-propellers, which was critical to maintain the stability and orientation of LRP6's first two YWTD-EGF domains. Early studies revealed that the interaction of LRP6 with Wnt-Fzd4 was mediated by the first two propeller domains [88], while other researchers pointed out that a single LRP6 might engage two different Wnt proteins simultaneously. LRP5/6 binds to different Wnts via different regions or multiple domains together [89]. The four β-propeller domains in LRP5/6 share a relatively low identity among them, indicating the functional differences among these YWTD propellers. Ke et al. demonstrated that Norrin interacted with β-propeller domain 1 (BP1) and β-propeller domain 2 (BP2) but not BP3-4 of LRP6. However, the binding sites of Norrin with LRP5 remain unclear. From these two perspectives, the mutations accumulated in the second YWTD-EGF domain may destroy the stable structure of first two β-propellers or interrupted their interaction with Norrin or Fzd4.

3.4. TSPAN12 Gene, Protein, and Spectrum

The TSPAN12 gene is located on chromosome 7q31 and encodes for a 305 amino acid transmembrane protein. TSPAN12 is a member of the tetraspanin family that shares certain specific structural features that distinguishes them from other proteins that pass the membrane four times. Both the N and C terminals of TSPAN12 were inside the cell membrane, and it has an unusually long C-terminal intracellular tail of approximately 60 amino acids. It contains four transmembrane domains connected by two extracellular loops (ECL-1 and ECL-2) and an intracellular loop. The ECL-1 is smaller compared to the ECL-2. TSPAN12 was discovered to associate selectively with Norrin/β-catenin signaling but not with Wnt/β-catenin signaling. It acted as the fourth important component of Norrin/FZD4/LRP5 complex. Signaling reduction could be rescued by TSPAN12 overexpression although direct binding with Norrin and FZD4 was not detected. However, another study reported that TSPAN12 interacted with Norrin and FZD4 via its extracellular loops and enhanced the FZD4 ligand selectivity for NDP [90]. Thus, TSPAN12 was postulated to elicit physiological levels of signaling that was required for normal retinal angiogenesis by promoting FZD4 multimerization cooperated with Norrin and facilitating selective ligand recognition [11]. We summarized 40 currently known mutations in TSPAN12 identified in patients affected with FEVR and discussed their coding consequences [6, 24, 29, 31, 54, 58, 59, 68, 83, 91–96] (Table 4 and Figure 5). All types of mutations were identified, including 22 missense mutation, 4 nonsense mutations, 9 splice-site mutations, 3 deletions, and 2 insertions. Mutations at residues T49, L140, C189, and L233 were reported more than one time. It was reported that L233P strongly impaired the TSPAN12 activity, while T49M mildly impaired the activity. Unfortunately, the authors did not investigate the signaling defect strength of L140X and C189Y/R. In all of the mutations, 38% (15 in 40 mutations) of them were located in the ECL-2 domain. These mutations were highly consistent with the biochemical results. TSPAN12 is anchored to the Norrin receptor complex via an interaction of the LEL with FZD4. The ECL-2 domain of TSPAN12 is essential for enhancing Norrin-induced FZD4 signaling. TSPAN12 can also alleviate the defects of FZD4 M105V, a mutation that destabilizes the NDP/FZD4 interaction [90].
Table 4

Spectrum of TSPAN12 gene mutations among patients with familial exudative vitreoretinopathy.

StudiesNo. of patientsNo. of mutationsDNA variantCoding effectLocation of the amino residueMutant phenotypesCountry of origin
Savarese et al. [94]11c.668T>Cp.L223PTransmembrane domainNo sign of neovascularizationPakistan

Poulter et al. [93]585c.67-1G>Cp.L23GfsX66Transmembrane domain, premature terminationBilateral retinal foldsMexican and Pakistan
c.146C>Tp.T49MFirst extracellular loopBilateral congenital cataract, large retinal fold
c.285 + 1g>ap.R50DfsX12Premature terminationBilateral congenital cataract, large retinal fold
c.413A>Gp.Y138CSecond extracellular loopPeripheral retina avascularity
c.668T>Cp.L223PTransmembrane domainBilateral retinal folds, funnel retinal detachments

Poulter et al. [6]707c.68T>Gp.L23XTransmembrane domainBilateral retinal folds and unilateral, persistent hyperplastic primary vitreousUSA, UK, Britain, Japan, Australia
c.149 + 3a>gSplice-site mutationPremature terminationUnilateral retinal fold
c.218_219insGCTGTTTp.F73LfsX119Premature terminationMacula ectopia, with a large retinal fold
c.302T>Ap.L101HTransmembrane domainLassic signs of FEVR
c.361-5_361-1delaccagSplice-site mutationPremature terminationBilateral temporal retinal avascularity
c.419T>Ap.L140XSecond extracellular loopBilateral retinal folds
c.629T>Gp.M210RBilateral macular tractionBilateral macular traction

Nikopoulos et al. [68]432c.709G>Cp.A237PTransmembrane domainAvascular peripheral retinaNetherlands
c.562G>Cp.G188RSecond extracellular loopAvascular peripheral retina

Yang et al. [96]493c.146C>Tp.T49MFirst extracellular loop, conserved residueFalciform retinal foldsChina
c.313T>Cp.C105RTransmembrane domain, conserved residueMidperipheral retina, an avascular zone on the peripheral retina
c.601delCp.L201FfsX14Conserved residueInferotemporal dragging of the optic disc and macula

Gal et al. [91]641c.542G>Tp.C181FSecond extracellular loop, form disulfide bondsBilateral visual impairment, various ocular abnormalitiesIsrael
Xu et al. [95]853c.177delCp.Y59fsX67Premature terminationFalciform retinal foldsChina
c.C254Tp.T85MIntracellular loopPigment deposit, dragged disc
c.566G>Ap.C189YSecond extracellular loop, form disulfide bondsBilateral retinal folds

Kondo et al. [92]902c.419T>Ap.L140XSecond extracellular loopAbnormal retinal vessels with vitreous degenerationJapan
c.734T>Cp.L245PC-terminal cytoplasmic tailRetinal fold resulting

Seo et al. [59]511c.56T>Gp.L19RTransmembrane domain3A stage FEVRKorea

Ganeswara Rao Musada et al. [2016]1103c.125T>Cp.V42AFirst extracellular loopDiagnosed with FEVR, symptoms not mentionedIndia
c.334G>Ap.V112ISecond extracellular loopDiagnosed with FEVR, symptoms not mentioned
c.479G>Ap.C160YSecond extracellular loopDiagnosed with FEVR, symptoms not mentioned

Tang et al. [31]1008c.2T>Cp.M1TN-terminal domainNot mentionedChina
c.464G>Cp.R155TSecond extracellular loopNot mentioned
c.438-439insTp.T147YfsX12Premature terminationTotal retinal detachment and massive vitreous proliferation
c.655delCp.Q219NfsX5Premature terminationTotal retinal detachment
c.916-918 + 3delTAAAAAp.∗306Eext∗35Elongated proteinPeripheral avascular retina
c.150-1G>ASplice acceptor mutationsNot applicatedNot mentioned
c.285 + 1G>ASplice acceptor mutationsNot applicatedNot mentioned
c.469-1G>ASplice acceptor mutationsNot applicatedNot mentioned

Iarossi et al. [24]81c.67-2A>GDefective splicingNot applicatedFalciform retinal foldItalia

Rao et al. [29]311c.345T>Gp.Y115XSecond extracellular loopFalciform folds, complete retinal detachmentChina

Liu et al. [83]101c.566G>Ap.C189YSecond extracellular loopChina

Schatz and Khan [58]31c.565T>Cp.C189RSecond extracellular loop, affects cystine residues formingTotal retinal detachmentSweden
Figure 5

Schematic diagram of the TSPAN12 protein shows the location of the 31 known mutations within the protein domains. Nine splice-site mutations besides one mutation (c.916-918 + 3delTAAAAA) resulting in protein extension and one mutation (c.67-1G>C) resulting in frame shift are not shown in this diagram. Superscript number means the reported times of the same or different mutations at a certain site. The color of the mutations which were reported more than one time was recolored as orange. The opacity varied with the reported frequency of the mutations.

4. Discussion

FEVR causing NDP, FZD4, LRP5, and TSPAN12 mutations was reported from 15 countries including USA, UK, China, Spain, India, Australia, Mexico, Japan, Netherlands, Italy, Canada, Korea, Sweden, Pakistan, and Israel. Top three countries with the largest number of reported mutations about NDP, FZD4, LRP5, and TSPAN12 genes were China, Netherlands, and Japan. The number of reported mutations did not completely match the population, since the three most populous countries were China, India, and USA. One of the major reasons contributing to this phenomenon might be the number of research groups was more in China, Netherlands, and Japan than that in other regions. Although most of the mutations were reported by only one study just once, some specific mutations were more common than others. For example, mutations of NDP at c.362G (p.R121) was independently reported by 5 different studies and distributed in Spanish, Indian, Mexican, Chinese, and Italian. FZD4 c. 313A>G (p.M105V) was reported for 8 times by 8 different research groups. Thus, it is significant to investigate the structure and function changes of the coding protein which resulted by the widely reported mutations. Although the mutations scattered widely through the whole genes, they have an inclination to distribute in certain areas. From the point of view of the coding proteins, the mutations concentrated at the N-terminal and C-terminal domains of Norrin. There were 19 mutations located in domains from C39 to C65 and C96 to C126, which covered the two β-hairpins (β1-β2 and β5-β6) and loops between and was crucial for binding with FZD4-CRD, namely, 73% of the mutations (19/26) concentrated in the interacting domains with FZD4-CRD. In terms of FZD4, 49% (59 of 121 mutations) of the mutations were positioned in the extracellular domain, which played a significant role in ligand recognition, while 13% (16 of 121 mutations) of the mutations were positioned in the intracellular domain which recruited Dishevelled to activate downstream signaling. The sum of mutations from the two domains accounted for 61% of total reported mutations. The tendency of mutations accumulating in certain domains was more obvious in regard to LRP5 protein. More than a third of reported mutations (38%, 22/58) were found from the second YWTD-type β-propeller domain and EGF domain, which were comprised of approximately 300 amino acids, accounting for less than 20% of whole LRP5 protein. But whether the second YWTD-EGF domains interacted with Norrin and FZD4 directly or not remained unknown. As far as TSPAN12 was concerned, it seemed that the mutations were intensively located in the ECL-2 domain (38%, 15/40). A recent study revealed that the large extracellular loop of TSPAN12 is required for enhancing Norrin-induced FZD4 signaling. In conclusion, the “hotspots” where mutations clustered were highly consistent with the domains participating protein interactions. Overall, mutations in NDP, FZD4, LRP5, and TSPAN12 genes explained up to ∼50% of all FEVR cases worldwide [97]. Besides the four genes we reviewed in this review, ZNF408, KIF11, RCBTB1, CTNNB1, and JAG1 were also reported to be the disease-causing genes of FEVR. The proteins encoded by NDP, FZD4, LRP5, TSPAN12, and CTNNB1 genes participate in the Norrin/β-catenin pathway, the signaling which is critical for retinal angiogenesis by controlling retinal vascular growth and architecture. The connection of proteins coded by ZNF408, KIF11, and RCBTB1 genes with the Norrin/β-catenin pathway was still unclear. A comprehensive spectrum covering other four causative genes (ZNF408, KIF11, RCBTB1, and CTNNB1) and further investigation on the biochemical functions of their coding proteins will undoubtedly facilitate thorough understanding of the pathogenic mechanism of FEVR. Pathogenic mutations in NDP and FZD4 lead to a number of retina-related diseases including FEVR, Norrie disease, persistent hyperplastic primary vitreous, advanced stage of retinopathy of prematurity, and Coats disease. These diseases can be diagnosed according to their unique symptoms which can be distinguished from FEVR [98]. The common characteristic of these NDP and FZD4 related diseases was defects in the vascularization of the retina. Further study on the role of the Norrin/β-catenin pathway in the retinal vascular may promote the understanding of the mechanism of the pathogenic mutations [12]. Furthermore, other sprouting angiogenesis associated components will in some way help provide in-depth insight about these retina-related diseases.
  6 in total

Review 1.  LRPs in WNT Signalling.

Authors:  Gary Davidson
Journal:  Handb Exp Pharmacol       Date:  2021

2.  Atypical Adams-Oliver syndrome with typical ocular signs of familial exudative vitreoretinopathy.

Authors:  En-Zhong Jin; Lyu-Zhen Huang; Ming-Wei Zhao; Hong Yin
Journal:  Int J Ophthalmol       Date:  2022-08-18       Impact factor: 1.645

Review 3.  Spectrum of Mutations in NDP Resulting in Ocular Disease; a Systematic Review.

Authors:  James Wawrzynski; Aara Patel; Abdul Badran; Isaac Dowell; Robert Henderson; Jane C Sowden
Journal:  Front Genet       Date:  2022-05-16       Impact factor: 4.772

4.  Ocular phenotype and genetical analysis in patients with retinopathy of prematurity.

Authors:  Tianchang Tao; Xianfen Meng; Ningda Xu; Jiarui Li; Yong Cheng; Yi Chen; Lvzhen Huang
Journal:  BMC Ophthalmol       Date:  2022-01-12       Impact factor: 2.209

5.  A Survey of Multigenic Protein-Altering Variant Frequency in Familial Exudative Vitreo-Retinopathy (FEVR) Patients by Targeted Sequencing of Seven FEVR-Linked Genes.

Authors:  Amanda Petrelli Cicerone; Wendy Dailey; Michael Sun; Andrew Santos; Daeun Jeong; Lance Jones; Konstaninos Koustas; Mary Drekh; Keaton Schmitz; Naomi Haque; Jennifer A Felisky; Alvaro E Guzman; Kendra Mellert; Michael T Trese; Antonio Capone; Kimberly A Drenser; Kenneth P Mitton
Journal:  Genes (Basel)       Date:  2022-03-11       Impact factor: 4.096

6.  Whole exome sequencing revealed 14 variants in NDP, FZD4, LRP5, and TSPAN12 genes for 20 families with familial exudative vitreoretinopathy.

Authors:  Handong Dan; Dongdong Wang; Zixu Huang; Qianqian Shi; Miao Zheng; Yuanyuan Xiao; Zongming Song
Journal:  BMC Med Genomics       Date:  2022-03-11       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.